These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 21946392

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.
    Yanagi M, Tamura K, Fujikawa T, Wakui H, Kanaoka T, Ohsawa M, Azushima K, Maeda A, Kobori H, Umemura S.
    Hypertens Res; 2013 Mar; 36(3):262-9. PubMed ID: 23154587
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.
    Zeymer U, Dechend R, Deeg E, Kaiser E, Senges J, Pittrow D, Schmieder R, 3A Registry Investigators.
    Int J Clin Pract; 2012 Mar; 66(3):251-61. PubMed ID: 22321062
    [Abstract] [Full Text] [Related]

  • 50. Efficacy of aliskiren in Japanese chronic kidney disease patients with hypertension.
    Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Mizuno K.
    Ren Fail; 2012 Mar; 34(4):442-7. PubMed ID: 22260457
    [Abstract] [Full Text] [Related]

  • 51. [Urinary L-type fatty acid binding protein (L-FABP) as a new urinary biomarker promulgated by the Ministry of Health, Labour and Welfare in Japan].
    Kamijo-Ikemori A, Ichikawa D, Matsui K, Yokoyama T, Sugaya T, Kimura K.
    Rinsho Byori; 2013 Jul; 61(7):635-40. PubMed ID: 24205707
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial.
    Lizakowski S, Tylicki L, Renke M, Rutkowski P, Heleniak Z, Sławińska-Morawska M, Aleksandrowicz E, Łysiak-Szydłowska W, Rutkowski B.
    Int Urol Nephrol; 2012 Dec; 44(6):1763-70. PubMed ID: 23326865
    [Abstract] [Full Text] [Related]

  • 56. Efficacy of add-on therapy of aliskiren to an angiotensin II receptor blocker on renal outcomes in advanced-stage chronic kidney disease: a prospective, randomized, open-label study.
    Soji K, Doi S, Nakashima A, Sasaki K, Kawai T, Aoki A, Kyuden Y, Fujiwara K, Yokoyama Y, Masaki T.
    Clin Exp Nephrol; 2015 Aug; 19(4):631-8. PubMed ID: 26293451
    [Abstract] [Full Text] [Related]

  • 57. Renoprotective effect of telmisartan in patients with chronic kidney disease.
    Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Node K.
    Clin Exp Hypertens; 2008 Oct; 30(7):662-72. PubMed ID: 18855269
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Is there a role for direct renin inhibitors in chronic kidney disease?
    Peixoto AJ, Orias M.
    Curr Opin Nephrol Hypertens; 2009 Sep; 18(5):397-403. PubMed ID: 19584722
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.